ERBB2 and breast cancer: Therefore, it hints at a demand to understand the distinction among HER2-zero, HER2-low and HER2-positive tumors in clinicopathological characteristics, pathological complete response (pCR) and long-term survival outcomes for locally advanced breast cancer receiving neoadjuvant chemotherapy.